Advantages of novel BioMimeTM Sirolimus Eluting Coronary Stent system. Moving towards biomimicry.
Since the first reported use of percutaneous transluminal coronary angioplasty (PTCA), advancements in interventional cardiology arena have been fast paced. Within the last ten years, these developments have been exponential. Developers & clinicians are fast adapting from the learning curve awarded by the time course of DES evolution. In that light BioMimeTM Sirolimus Eluting Coronary Stent comes as a fresh thought in taking stents towards a biomimicry concept. The stent is built on an ultra-low strut thickness (65 µm) cobalt chromium stent platform, using an intelligent hybrid of close and open cells allowing for morphology mediated expansion, employs a well known anti-proliferative - Sirolimus that elutes from a biodegradable co-polymer formulation in 30 days and ensures high coating integrity and low coating thickness of 2 µm. The resultant stent demonstrates almost 100% endothelialization at 30 days in preclinical model and zero percent MACE >18 months in the primary efficacy and safety clinical study.
Fortis Escorts Heart Institute and Research Centre, New Delhi, India. kaul.upendra@gmail.com
K
K
Upendra
B
B
Sanjeev
D000818:Animals; D040761:Biomimetic Materials; D003324:Coronary Artery Disease / Q000601:surgery; D054855:Drug-Eluting Stents; D042783:Endothelial Cells; D006801:Humans; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage*
D020123:Sirolimus